Pharmacosmos A/S: Iron Deficiencies trials

The registry lists 19 Iron Deficiencies studies with Pharmacosmos A/S as lead sponsor. 2 are open to participants now and 7 have results posted.

Phase 1 1Phase 3 13Phase 4 2No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart FailureRecruitingNCT06929806Phase 3
• Multi-center Trial of Ferric Derisomaltose in Children 0 to <18 Years of Age With Iron Deficiency AnemiaRecruitingNCT05179226Phase 3
• Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency AnaemiaCompletedNCT03238911Phase 3Results posted
• Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency AnaemiaCompletedNCT03237065Phase 3Results posted
• An Extension Trial to Assess the Safety of Re-dosing of Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®)CompletedNCT02962648Phase 3Results posted
• Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA)CompletedNCT02940886Phase 3Results posted
• Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney DiseaseCompletedNCT02940860Phase 3Results posted
• IDA-01 A Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron SucroseCompletedNCT02130063Phase 3Results posted
• Iron Isomaltoside 1000 (Monofer®) in Non-Dialysis Dependent Chronic Kidney Disease and With Renal-Related AnaemiaCompletedNCT01102413Phase 3Results posted
• A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel DiseaseCompletedNCT03466983Phase 4
• Intravenous Iron Isomaltoside Versus Oral Iron Supplementation for Treatment of Iron Deficiency in Pregnancy.CompletedNCT03188445Phase 4
• Dose-escalation Trial of the Safety, Pharmacokinetics, and Pharmacodynamics of Iron Isomaltoside (Monofer®)CompletedNCT03013439Phase 1
• Time to Relapse of Iron Deficiency Anaemia After Standard Treatment With The Intravenous Iron (Monofer®)CompletedNCT02546154
• A Non-interventional Study of Diafer in Subjects With CKD on Haemodialysis for Treatment of Iron DeficiencyCompletedNCT02301026
• A Randomized, Double-blind, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Against PlaceboWithdrawnNCT02172001Phase 3
• Time to Relapse of Iron Deficiency Anemia After Standard Treatment With a New Intravenous Iron (Monofer®)CompletedNCT01900197
• A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by Infusions to Iron-deficient Blood DonorsCompletedNCT01895231Phase 3
• Iron Oligosaccharide in Inflammatory Bowel Disease Subjects With Iron Deficiency AnaemiaCompletedNCT01017614Phase 3
• A Study of Iron Oligosaccharide in Chronic Kidney Disease PatientsCompletedNCT00536666Phase 3